CHF Solutions Applauds U.S Congress Request to U.S. International Trade Commission to Identify Products to Treat COVID-19
August 27 2020 - 8:15AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
improving the lives of patients suffering from fluid overload,
today commended a request from the U.S. Congress to the U.S.
International Trade Commission (USITC) concerning the availability
of U.S.-sourced medical supplies to treat COVID-19 and future
pandemics.
Following up on prior USITC reports, the House Committee on Ways
and Means and Senate Committee jointly issued a formal request on
August 13, 2020, calling on USITC to conduct a follow-on
investigation and prepare a report to Congress, which is expected
to aid Congress in making “critical policymaking decisions”
concerning U.S. COVID-related industry sectors, including the
medical device industry.
“CHF Solutions is grateful for Congress’ important efforts to
ensure medical supply security and identify U.S. sources for
products needed by our dedicated healthcare professionals treating
critically-ill patients with COVID-19,” said John Erb, CEO of CHF
Solutions. “As the country continues to manage patient care during
this pandemic, the Aquadex SmartFlow™ system, manufactured in
Minnesota, has been used in several hospitals to treat fluid
management for COVID-19 patients, especially when dialysis
equipment and staff are limited.”
As recently cited, isolated ultrafiltration is an optimal
strategy that primarily focuses on fluid extraction and
optimization of volume status.1 The Aquadex SmartFlow system, a
portable ultrafiltration device with small extracorporeal volume
(i.e. 35 ml), provides a predictable method for fluid extraction,
making it more likely to achieve precise fluid balance in COVID-19
patients. Providers can specify and adjust the exact amount
and rate of fluid to be removed from each patient.
1 https://pubmed.ncbi.nlm.nih.gov/32336959/
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated
to changing the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the outcome of the report from the
U.S. International Trade Commission. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our expectations regarding the potential impacts of the COVID-19
pandemic on our business operations, our ability to execute on our
commercial strategy, the possibility that we may be unable to raise
sufficient funds necessary for our anticipated operations, our
post-market clinical data collection activities, benefits of our
products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024